CY1121275T1 - TREATMENT OF ADDICTION DISORDERS AND IMPACT CONTROL USING PDE7 SUSPENSES - Google Patents
TREATMENT OF ADDICTION DISORDERS AND IMPACT CONTROL USING PDE7 SUSPENSESInfo
- Publication number
- CY1121275T1 CY1121275T1 CY20191100214T CY191100214T CY1121275T1 CY 1121275 T1 CY1121275 T1 CY 1121275T1 CY 20191100214 T CY20191100214 T CY 20191100214T CY 191100214 T CY191100214 T CY 191100214T CY 1121275 T1 CY1121275 T1 CY 1121275T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pde7
- treatment
- suspenses
- addiction disorders
- impact control
- Prior art date
Links
- 206010012335 Dependence Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 101100407335 Dictyostelium discoideum pde7 gene Proteins 0.000 title 1
- 102000010984 Type 7 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 2
- 108010037622 Type 7 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Αυτή η αποκάλυψη κατευθύνεται στη θεραπεία του εθισμού και των πρωτογενών διαταραχών ελέγχου της παρορμητικότητας χρησιμοποιώντας αναστολείς φωσφοδιεστεράσης 7 (PDE7), μόνο ή σε συνδυασμό με άλλους θεραπευτικούς παράγοντες.This disclosure is directed to the treatment of addiction and primary impulsivity control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261643611P | 2012-05-07 | 2012-05-07 | |
| US13/835,607 US9220715B2 (en) | 2010-11-08 | 2013-03-15 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| PCT/US2013/039866 WO2013176877A2 (en) | 2012-05-07 | 2013-05-07 | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121275T1 true CY1121275T1 (en) | 2020-05-29 |
Family
ID=55442549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100214T CY1121275T1 (en) | 2012-05-07 | 2019-02-20 | TREATMENT OF ADDICTION DISORDERS AND IMPACT CONTROL USING PDE7 SUSPENSES |
Country Status (11)
| Country | Link |
|---|---|
| JP (4) | JP2016138137A (en) |
| CY (1) | CY1121275T1 (en) |
| DK (1) | DK2846805T3 (en) |
| ES (1) | ES2711949T3 (en) |
| HK (1) | HK1208373A1 (en) |
| HR (1) | HRP20190279T1 (en) |
| HU (1) | HUE043518T2 (en) |
| LT (1) | LT2846805T (en) |
| NZ (1) | NZ628130A (en) |
| PT (1) | PT2846805T (en) |
| RU (1) | RU2665134C2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023027157A1 (en) | 2021-08-27 | 2023-03-02 | 住友金属鉱山株式会社 | Infrared curable ink composition, infrared cured product and method for producing infrared cured product |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10148233A1 (en) * | 2001-09-28 | 2003-04-10 | Boehringer Ingelheim Pharma | Compounds to reduce excessive food intake |
| US7915285B2 (en) * | 2005-09-26 | 2011-03-29 | The Regents Of The University Of Colorado | Method for treating drug and behavioral addictions |
| US20080260643A1 (en) * | 2007-03-27 | 2008-10-23 | Omeros Corporation | Use of pde7 inhibitors for the treatment of movement disorders |
| US8637528B2 (en) * | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| CA2684059C (en) * | 2007-04-11 | 2016-07-12 | Omeros Corporation | Use of a ppary agonist, alone or in combination, for the treatment or prophylaxis of addictions |
-
2013
- 2013-05-07 NZ NZ628130A patent/NZ628130A/en unknown
- 2013-05-07 RU RU2014149192A patent/RU2665134C2/en active
- 2013-05-07 HU HUE13793319A patent/HUE043518T2/en unknown
- 2013-05-07 PT PT13793319T patent/PT2846805T/en unknown
- 2013-05-07 LT LTEP13793319.8T patent/LT2846805T/en unknown
- 2013-05-07 DK DK13793319.8T patent/DK2846805T3/en active
- 2013-05-07 ES ES13793319T patent/ES2711949T3/en active Active
-
2015
- 2015-09-18 HK HK15109162.6A patent/HK1208373A1/en unknown
-
2016
- 2016-05-06 JP JP2016092956A patent/JP2016138137A/en not_active Withdrawn
-
2017
- 2017-07-10 JP JP2017134611A patent/JP6963431B2/en active Active
-
2019
- 2019-02-12 HR HRP20190279TT patent/HRP20190279T1/en unknown
- 2019-02-20 CY CY20191100214T patent/CY1121275T1/en unknown
- 2019-06-06 JP JP2019106083A patent/JP2019142980A/en active Pending
-
2021
- 2021-06-16 JP JP2021100157A patent/JP2021138766A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT2846805T (en) | 2019-02-27 |
| HK1208373A1 (en) | 2016-03-04 |
| RU2014149192A (en) | 2016-07-10 |
| JP2016138137A (en) | 2016-08-04 |
| LT2846805T (en) | 2019-02-25 |
| NZ628130A (en) | 2017-02-24 |
| JP2019142980A (en) | 2019-08-29 |
| ES2711949T3 (en) | 2019-05-08 |
| HUE043518T2 (en) | 2019-08-28 |
| HRP20190279T1 (en) | 2019-04-05 |
| DK2846805T3 (en) | 2019-03-18 |
| RU2665134C2 (en) | 2018-08-28 |
| JP2017171691A (en) | 2017-09-28 |
| JP6963431B2 (en) | 2021-11-10 |
| JP2021138766A (en) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125436T1 (en) | DNA-PK INHIBITORS | |
| CY1124311T1 (en) | DNA-PK INHIBITORS | |
| CY1120246T1 (en) | METHODS OF METALENZYME INHIBITORS | |
| CY1124144T1 (en) | COMPOSITIONS AND METHODS FOR TREATING CEREBRIAL EPISODE IN A SUBJECT ON CONCOMITANEOUS STATIN THERAPY | |
| CY1124729T1 (en) | PHARMACEUTICAL FORMS OF ENZALUTHAMIDE | |
| CY1117678T1 (en) | METHODS OF METALENZYME INHIBITORS | |
| CY1124307T1 (en) | PHARMACEUTICAL COMPOSITION, METHODS OF THERAPY AND USES THEREOF | |
| CY1123051T1 (en) | TAPENTADOL FOR THE PREVENTION AND TREATMENT OF DEPRESSION AND ANXIETY | |
| CY1124407T1 (en) | AUTOTAXIN INHIBITOR COMPOUNDS | |
| CY1121076T1 (en) | TRICYCLIC COMPOUNDS AS ANTI-CANCER AGENTS | |
| CY1121065T1 (en) | IVAT INHIBITORS FOR THE TREATMENT OF US DISEASES | |
| CY1120556T1 (en) | BICYCLE HYDROCYCLES AS FGFR SUSPENSIONS | |
| CY1121653T1 (en) | C1-INH COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF DISORDERS ASSOCIATED WITH C1 ESTERASE INHIBITOR DEFICIENCY | |
| EA201391351A1 (en) | METHODS OF INCREASING THE EFFICIENCY OF FOLR1 CANCER THERAPY | |
| CY1116703T1 (en) | USE OF SGC STIMULATORS, SGC ACTIVATORS, ONLY AND IN CONNECTION WITH PDE5 INHIBITORS FOR THERAPEUTIC SYSTEM TREATMENT | |
| EA201500362A1 (en) | RHO-KINASE INHIBITORS | |
| TN2016000057A1 (en) | Methods of treating sporadic inclusion body myositis | |
| MX351943B (en) | Metalloenzyme inhibitor compounds. | |
| EA201790273A1 (en) | FLAGELLIN COMPOSITIONS AND THEIR APPLICATION | |
| BR112014021104A2 (en) | methods and compositions for the treatment of huntington's disease | |
| CY1120751T1 (en) | RORC2 HETERODYCYLOLEL INHIBITORS AND METHODS OF USING THEM | |
| MA40620A (en) | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION | |
| CY1117654T1 (en) | POLYETHYLENE GLYCLENED APRELINE AND USES thereof | |
| CY1120877T1 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABDOMINAL | |
| RS53893B1 (en) | Use of biotin for the treatment of multiple sclerosis |